Trial Profile
A Randomized Placebo-Controlled Phase II Trial Comparing Gemcitabine Monotherapy to Gemcitabine in Combination With AZD 1775 (MK 1775) in Women With Recurrent, Platinum Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 13 Mar 2024
Price :
$35
*
At a glance
- Drugs Adavosertib (Primary) ; Gemcitabine (Primary)
- Indications Adenocarcinoma; Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 21 Feb 2024 Planned End Date changed from 4 Feb 2024 to 20 Feb 2025.
- 21 Feb 2024 Planned End Date changed from 4 Feb 2024 to 20 Feb 2025.
- 06 Sep 2023 Planned End Date changed from 4 Feb 2023 to 4 Feb 2024.